Keytruda 100 MG/4 ML vial 4ML
Ended Awarded Last action
- Contract number
- SPE2DR26FDJP5
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $104,947
Award facts
- Contract value 100% obligated
- $104,947.08 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency has awarded a firm fixed-price delivery order valued at approximately $105K to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Keytruda 100 mg/4 mL vials. The delivery order, issued on January 22, 2026, with an ultimate completion date of February 12, 2026, carries no set-aside designation, indicating the award was made on a competitive basis. This delivery order is issued under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion government-wide acquisition vehicle established to provide comprehensive pharmaceutical supply support to Department of Defense military healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial performance across the federal pharmaceutical supply chain, with its IDC under PPV-G GEN V holding a $500M ceiling through December 31, 2036. The company's product portfolio encompasses oncology treatments, biologics, vaccines, specialty pharmaceuticals, and medical consumables critical to military medical operations. As a regional prime vendor contractor within the broader PPV-G GEN V acquisition strategy, DMS Pharmaceutical Group provides firm fixed-price delivery orders enabling the Defense Logistics Agency to procure diverse pharmaceutical products to support recurring medical supply requirements across the global military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FDJP5?
SPE2DR26FDJP5 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 22, 2026.
How much is contract SPE2DR26FDJP5 worth?
The government has obligated $104,947 on SPE2DR26FDJP5.
Is contract SPE2DR26FDJP5 an order under another contract?
Yes. SPE2DR26FDJP5 is a delivery order under SPE2DR25D9144, an indefinite delivery contract.
Was contract SPE2DR26FDJP5 competed?
The extent of competition for SPE2DR26FDJP5 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award